🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  2. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  3. Study of U3-1402 in subjects with non-small cell lung cancer

    Daiichi Sankyo

    METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

    phase 1 other active

    1 trial

  4. Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

    Genmab A/S

    Advanced solid tumors

    phase 1 other active

    1 trial

  5. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  6. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  7. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    AbbVie Deutschland GmbH & Co. KG

    Select B-Cell malignancies.

    phase 1 other active

    1 trial

  8. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  9. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  10. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

    IONIS PHARMACEUTICALS INC

    Multiple System Atrophy

    phase 1 other active

    1 trial

  11. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  12. Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

    The George Institute

    Idiopathic Pulmonary Fibrosis

    phase 1 other active

    1 trial

  13. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  14. Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or refractory multiple myeloma

    phase 1 other active

    1 trial

  15. Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  16. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  17. TAK-137 5 mg tablet, TAK-137 placebo tablet

    Takeda

    Healthy Japanese Adult Male

    phase 1 small molecule terminated

    1 trial

  18. TAK-329

    Takeda

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  19. TAK-536 Tablet

    Takeda

    Japanese Healthy Adult Males

    phase 1 small molecule completed

    1 trial

  20. TAK-648

    Takeda

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  21. TAK-648 Tablet

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  22. TAK-831 Oral Tablet

    NEUROCRINE BIOSCIENCES INC

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  23. TAK-831 Tablet T2

    NEUROCRINE BIOSCIENCES INC

    Healthy

    phase 1 small molecule completed

    1 trial

  24. TAK-935 Oral Tablet

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources